The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral Researcher Position”
Reference: Ref. 67-2022
Application deadline: 31.01.2023
Number of vacancies: 1
A postdoctoral position is available at the Tumor Biomarkers group at Vall d´Hebrón Institute of Oncology (VHIO). The Tumor Biomarkers group, led by Dr. Josep Villanueva, is interested in the characterization of the mechanisms adopted by cancer cells to communicate amongst themselves as well as with their microenvironment during tumorigenesis, and exploit these data to advance biomarker and drug target discovery. Recently, the group has also been interested in the characterization of drug-tolerant persister breast cancer cells generated by cytotoxic drugs, and the acquired resistance mechanisms originated from their phenotypic evolution.
We are looking for an enthusiastic postdoctoral research scientist with a strong background in cancer biology. The specific research project for this position is aimed at developing a new antibody-drug conjugate to be used in cancer therapeutics.
- Scientific background in cancer biology, particularly interest in the HER family receptor biology
- Excellent writing and verbal communications skills in English
- The successful candidate will have organizational and analytical skill. Candidates should be highly motivated and team-oriented. The postdoctoral scientist is expected to design and perform the experiments to fulfill the research project.
Potential candidates should submit a curriculum vitae, letter of intent, and at least one reference using the form below or via email to email@example.com, including the reference “Ref. 67-2022” in the subject line of your email.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.